Bangalore, Oct 5 (UNI) Avestha Biotherapeutics and Research Pvt Ltd (ABRPL), a joint venture between Avesthagen and Meditab Specialities Ltd (CIPLA group), today announced the acquisition of Siegfried Biologics GmbH, a fully owned subsidiary of the Siegfried Group in Switzerland.
ABRPL, based in Bangalore, would manufacture a series of biopharmaceuticals for the global market with an initial focus on the BRIC markets.
This acquisition fits into the strategy of being able to manufacture under USFDA and EMEA compliant conditions, the company said in a release here.
The facility was expected to initially focus on biopharmaceuticals that were presently under development at Avesthagen through the Avesthagen-Cipla joint venture agreement that was signed in May 2004.
Siegfried Biologics GmbH, based in Berlin, was started ten years ago as a contract manufacturing organisation (CMO). The 50-plus team of people had a solid background and extensive experience in the development of biologics from cell line generation, upstream process development and scale-up to GMP manufacturing, the release said.